Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
|Slideshows|June 25, 2019
- Drug Topics June 2019
- Volume 163
- Issue 6
Five Tech Best Practices
Author(s)Fred Gebhart
Advertisement
Articles in this issue
over 7 years ago
Opinion: Data is a Vital Resource in Fighting the Opioid Crisisover 7 years ago
Why Technology Upkeep is Up to Youover 7 years ago
New Drug Review: Zulresso (Brexanolone)over 7 years ago
Opinion: The Future of Pharmacyover 7 years ago
Discount Drug Cards Are Flourishingover 7 years ago
How to Keep Your Professional Development Currentover 7 years ago
10 Ways to Boost Customer Loyaltyover 7 years ago
Opinion: PharmD Quality vs Quantityover 7 years ago
On the Road to Provider Statusover 7 years ago
Five Tips for Evaluating Clinical StudiesAdvertisement
Related to this article
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.
In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
3
FDA Approves Brytly for OTC Eye Redness Relief
4
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
5